Skip to main content

Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).

Publication ,  Journal Article
Brown, JC; Zhang, S; Niedzwiecki, D; Saltz, LB; Mayer, RJ; Mowat, RB; Whittom, R; Hantel, A; Benson, A; Atienza, D; Messino, M; Kindler, H ...
Published in: JNCI Cancer Spectr
February 2018

BACKGROUND: Energy balance-related risk factors for colon cancer recurrence and mortality-type II diabetes, hyperinsulinemia, inflammation, and visceral obesity-are positively correlated with consumption of refined grains and negatively correlated with consumption of whole grains. We examined the relationship between the consumption of refined and whole grains with cancer recurrence and mortality in a cohort of patients with colon cancer. METHODS: We conducted a prospective observational study of 1024 patients with stage III colon cancer who participated in a randomized trial of postoperative chemotherapy. Patients reported consumption of refined and whole grains using a food frequency questionnaire during and six months after chemotherapy. The primary outcome was disease-free survival (DFS). Multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox regression models. All P values are two-sided. RESULTS: During a median follow-up of 7.3 years, 394 patients experienced a DFS event. The hazard ratio for DFS was 1.56 (95% CI = 1.09 to 2.24) for patients consuming three or more servings per day of refined grains compared with patients consuming less than one serving per day (Ptrend = .005). The hazard ratio for DFS was 0.89 (95% CI = 0.66 to 1.20) for patients consuming three or more servings per day of whole grains compared with patients consuming less than one serving per day (Ptrend = .54). The hazard ratio for DFS of substituting one serving per day of refined grain with one serving per day of whole grain was 0.87 (95% CI = 0.79 to 0.96, P = .007). CONCLUSIONS: The choice of grain consumed may be associated with cancer recurrence and mortality. Future studies are necessary to confirm our findings and to inform the design of randomized trials.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JNCI Cancer Spectr

DOI

EISSN

2515-5091

Publication Date

February 2018

Volume

2

Issue

2

Start / End Page

pky017

Location

England

Related Subject Headings

  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Brown, J. C., Zhang, S., Niedzwiecki, D., Saltz, L. B., Mayer, R. J., Mowat, R. B., … Meyerhardt, J. A. (2018). Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). JNCI Cancer Spectr, 2(2), pky017. https://doi.org/10.1093/jncics/pky017
Brown, Justin C., Sui Zhang, Donna Niedzwiecki, Leonard B. Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, et al. “Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).JNCI Cancer Spectr 2, no. 2 (February 2018): pky017. https://doi.org/10.1093/jncics/pky017.
Brown JC, Zhang S, Niedzwiecki D, Saltz LB, Mayer RJ, Mowat RB, et al. Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). JNCI Cancer Spectr. 2018 Feb;2(2):pky017.
Brown, Justin C., et al. “Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).JNCI Cancer Spectr, vol. 2, no. 2, Feb. 2018, p. pky017. Pubmed, doi:10.1093/jncics/pky017.
Brown JC, Zhang S, Niedzwiecki D, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Li Y, Zhang X, Ng K, Willett WC, Giovannucci EL, Fuchs CS, Meyerhardt JA. Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). JNCI Cancer Spectr. 2018 Feb;2(2):pky017.

Published In

JNCI Cancer Spectr

DOI

EISSN

2515-5091

Publication Date

February 2018

Volume

2

Issue

2

Start / End Page

pky017

Location

England

Related Subject Headings

  • 3211 Oncology and carcinogenesis